USPTO serial 99023559
MEIRAGTX
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Feb 17, 2026
- Examiner
- REGAN, JOHN B
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with MEIRAGTX?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Michael J. Leonard
Michael J. Leonard Fox Rothschild LLP212 Carnegie Center, Suite 400Princeton, NJ 08540United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | chemical additives, namely, chemical auxiliary agents, carriers, and substances, all for use in the manufacture of pharmaceutical preparations | ACTIVE | — |
| 005 | pharmaceutical products for use in gene therapy; pharmaceutical preparations and substances for the treatment of neurological and neurodegerative diseases, ocular diseases and rare diseases, in the nature of rare kidney diseases, rare cardiovascular diseases, rare hepato-gastro-enterological diseases, rare immunodeficiencies, developmental defects, neuromuscular diseases, rare neurological diseases, rare cardiovascular diseases, rare lung diseases, rare bone diseases, rare sensory disorders, rare skin diseases, rare diseases of connective tissue, rare endocrine diseases, rare hereditary metabolic diseases, rare nonmalignant hematologic disorder, salivary gland conditions, oncology, autoimmune conditions, ageing, metabolic disease, obesity; auxiliary agents for pharmaceutical preparations, namely, small molecule compounds for use as drug delivery agents in pharmaceuticals; carriers for pharmaceutical preparations, namely, drug delivery agents consisting of compounds that facilitate delivery of pharmaceuticals; substances for pharmaceutical preparations, namely, namely, anti-infectives, anti-inflammatories, antibacterial pharmaceuticals, antibiotics, antifungal preparations, and antivirals; pharmaceutical preparations for the prevention and treatment of cardiovascular diseases; dermatological pharmaceutical preparations and substances; pharmaceutical preparations for the prevention and treatment of respiratory diseases and disorders; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations and substances for the prevention and treatment of gastro-intestinal diseases; pharmaceutical preparations for the prevention and treatment of diseases and disorders of the autoimmune system, the metabolic system, the endocrine system, the musculo-skeletal system and the genitourinary system; pharmaceutical preparations for use in hematology and in tissue and organ transplantation; pharmaceutical preparations for the prevention and treatment of eye diseases and conditions; pharmaceutical preparations for the prevention and treatment of heart rhythm disorders; pharmaceutical preparations for the prevention and treatment of immune system related diseases and disorders; pharmaceutical preparations for the prevention and treatment of kidney diseases; pharmaceutical preparations for the prevention and treatment of diabetes; pharmaceutical preparations for the prevention and treatment of hypertension; pharmaceutical preparations for the prevention and treatment of skin disorders; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for use in urology; pharmaceutical preparations and substances for ophthalmological use; pharmaceutical preparations and substances for the prevention and treatment of cancer and tumors; pharmaceutical preparations for the prevention and treatment of allergies; pharmaceutical preparations and substances for the prevention and treatment of bone diseases, salivary gland conditions, oncology, autoimmune conditions, aging, metabolic disease, and obesity; biological preparations for use in cell cultures for medical purposes | ACTIVE | — |
| 040 | Custom manufacture of human therapeutics, pharmaceuticals, biologicals and biopharmaceuticals | ACTIVE | — |
| 042 | scientific research in the field of genetics, gene therapy and genetic engineering; genetic testing for scientific research purposes; scientific advisory services relating to gene therapy research; scientific, biological, pharmaceutical and medical research services; laboratory research in the fields of genetics, drug development, biotechnology, microbiology and molecular biology; biochemical and biotechnological analysis services | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by MeiraGTx Limited
- Other trademarks owned by MeiraGTx Limited
- Other trademarks owned by MeiraGTx Limited
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 040
- Other trademarks in Class 042
- Similar marks named MEIRAGTX
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Feb 17, 2026 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Feb 17, 2026 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Dec 30, 2025 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Dec 30, 2025 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Dec 24, 2025 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Dec 2, 2025 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Nov 10, 2025 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Nov 10, 2025 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Nov 10, 2025 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Nov 10, 2025 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Oct 15, 2025 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Oct 15, 2025 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Oct 15, 2025 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jul 21, 2025 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 21, 2025 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 21, 2025 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 10, 2025 | DOCK | ASSIGNED TO EXAMINER | — |
| Jul 1, 2025 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jan 30, 2025 | NWAP | NEW APPLICATION ENTERED | — |
| Jan 30, 2025 | MAFR | APPLICATION FILING RECEIPT MAILED | — |